2023年,有关该项研究长期安全性和疗效持久性的2年随访结果,也已出炉:“Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia”,并于2023年4月发表于Journal of Hem...
近日,中国医学科学院血液病医院(中国医学科学院血液学研究所)冯晓明研究员与北京高博医院潘静主任等合作在《Nature Medicine》(IF=58.7)发表了题为“Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 t...
2023年,有关该项研究长期安全性和疗效持久性的2年随访结果,也已出炉:“Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia”,并于2023年4月发表于Journal of Hematology & Oncology(IF=23.168),治疗后24个月的无进展生存(PFS)率和总生存(OS)...
2022年3月25日,华中科技大学同济医学院戴振宇博士、穆伟博士与驯鹿生物研发VP谭涛超博士合作在《Signal Transduction and Targeted Therapy》发表了题为“T cells expressing CD5/CD7 bispecificchimeric antigen receptors with fully human heavy-chain-onlydomains mitigatetumor antigen escape”研究论文,文章中系统介绍了C...
近日,中国医学科学院血液病医院(中国医学科学院血液学研究所)冯晓明研究员与北京高博医院潘静主任等合作在《Nature Medicine》(IF=58.7)发表了题为“Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial”的研究论文,在国际上首次报道异体来源的CD5 CAR-T治疗r/r T-ALL的临...
截图来源:Signal Transduction and Targeted Therapy CAR-T细胞的概念开始于1990年代初,到目前为止已经更新迭代到第四代疗法。随着复星凯特、药明巨诺以及传奇生物等多种细胞治疗产品相继获批上市,细胞治疗迎来井喷时代。虽然CAR-T疗法在晚期B细胞恶性肿瘤和成人复发/难治性多发性骨髓瘤的治疗上有显著成效,但对于难治复发...
New Immune Checkpoint Protein Identified for Cancer Therapy Bacterial Protoplast-Derived Nanovesicles for Cancer Immunotherapy The Role of Immune Checkpoints in Antitumor Response Knockout of CD5 on CAR T Cells Boosts Anti-Tumor Efficacy Current Landscape and Future Directions of Bispecific Antibodies in ...
截图来源:Signal Transduction and Targeted Therapy CAR-T细胞的概念开始于1990年代初,到目前为止已经更新迭代到第四代疗法。随着复星凯特、药明巨诺以及传奇生物等多种细胞治疗产品相继获批上市,细胞治疗迎来井喷时代。虽然CAR-T疗法在晚期B细胞恶性肿瘤和成人复发/难治性多发性骨髓瘤的治疗上有显著成效,但对于难治复发...
Chimeric antigen receptor engineered T cells (CAR-T) have demonstrated promising clinical efficacy in B-cell malignancies, and the approach has been extended to T-cell malignancies. However, the use of allogeneic T cells in CAR therapy poses a challenge due to the risk of graft-versus-host dis...
Background CAR-T cell therapy has revolutionized the treatment of B-cell malignancies. However, the development of CAR-T therapies for T-cell malignancies has been slower, partially due to technical difficulties in T-cell antigen targeting CAR-T production such as fratricide and contamination of ...